DYNE THERAPEUTICS INC's ticker is DYN and the CUSIP is 26818M108. A total of 117 filers reported holding DYNE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2023 | $27,594,667 | +38.7% | 2,074,787 | -6.5% | 32.85% | +6.7% |
Q3 2023 | $19,891,505 | -20.4% | 2,220,034 | 0.0% | 30.79% | -5.6% |
Q2 2023 | $24,975,383 | -2.3% | 2,220,034 | 0.0% | 32.61% | -6.8% |
Q1 2023 | $25,574,792 | -0.6% | 2,220,034 | 0.0% | 34.99% | +1.2% |
Q4 2022 | $25,730,194 | -8.7% | 2,220,034 | 0.0% | 34.58% | +36.6% |
Q3 2022 | $28,194,000 | +38.6% | 2,220,034 | -25.0% | 25.30% | +47.3% |
Q2 2022 | $20,335,000 | -28.7% | 2,960,046 | 0.0% | 17.18% | +3.5% |
Q1 2022 | $28,535,000 | -18.9% | 2,960,046 | 0.0% | 16.60% | +26.1% |
Q4 2021 | $35,195,000 | -26.8% | 2,960,046 | 0.0% | 13.16% | -4.4% |
Q3 2021 | $48,071,000 | -22.8% | 2,960,046 | 0.0% | 13.77% | -11.8% |
Q2 2021 | $62,280,000 | +35.5% | 2,960,046 | 0.0% | 15.62% | +34.5% |
Q1 2021 | $45,970,000 | -26.0% | 2,960,046 | 0.0% | 11.61% | -9.0% |
Q4 2020 | $62,161,000 | +4.0% | 2,960,046 | 0.0% | 12.76% | -65.9% |
Q3 2020 | $59,764,000 | – | 2,960,046 | – | 37.43% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vida Ventures Advisors, LLC | 2,960,046 | $35,195,000 | 13.16% |
MPM ASSET MANAGEMENT LLC | 4,951,303 | $58,871,000 | 12.72% |
Atlas Venture Life Science Advisors, LLC | 8,934,902 | $106,236,000 | 9.76% |
Logos Global Management LP | 3,234,392 | $38,457,000 | 3.97% |
GREAT POINT PARTNERS LLC | 845,000 | $10,047,000 | 2.23% |
Deep Track Capital, LP | 2,292,250 | $27,255,000 | 1.92% |
Octagon Capital Advisors LP | 583,649 | $6,940,000 | 1.35% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 476,000 | $5,641,000 | 1.26% |
COMMODORE CAPITAL LP | 305,125 | $3,628,000 | 0.84% |
RA Capital Management | 2,805,045 | $33,352,000 | 0.59% |